(Q34477028)

2 August 2017

title

Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide (English)

1 reference

2 August 2017

Daniel Putzer

1

1 reference

2 August 2017

Alexander Kroiss

2

1 reference

2 August 2017

Dietmar Waitz

3

1 reference

2 August 2017

Michael Gabriel

4

1 reference

2 August 2017

Tatjana Traub-Weidinger

5

1 reference

2 August 2017

Christian Uprimny

6

1 reference

2 August 2017

Elisabeth von Guggenberg

7

1 reference

2 August 2017

Clemens Decristoforo

8

1 reference

2 August 2017

Boris Warwitz

9

1 reference

2 August 2017

Gerlig Widmann

10

1 reference

2 August 2017

Irene Johanna Virgolini

11

1 reference

2 August 2017

publication date

14 November 2012

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

2 August 2017

published in

1 reference

2 August 2017

volume

40

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

364-372

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-012-2286-6

2 August 2017

exact match

0 references

cites work

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Somatostatin analogs and radiopeptides in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Imaging of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Radiolabelling DOTA-peptides with 68Ga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2286-6

Clinical relevance of somatostatin receptor imaging

21 January 2018

1 reference

12 December 2020

Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals

1 reference

12 December 2020

A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract

1 reference

12 December 2020

New trends in peptide receptor radioligands

1 reference

12 December 2020

Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients

1 reference

12 December 2020

Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.

1 reference

12 December 2020

New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy

1 reference

12 December 2020

Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.

1 reference

12 December 2020

Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma

1 reference

12 December 2020

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

1 reference

12 December 2020

Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells

1 reference

12 December 2020

111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung

1 reference

12 December 2020

10.1007/S00259-012-2286-6

Identifiers

DOI

1 reference

2 August 2017

1 reference